On November 30 2017  Blueprint Medicines hosted an informational webcast for the GIST patient community about BLU-285, an investigational medicine for people with advanced GIST, in collaboration with GIST Support International.

During the webcast, Dr. Andy Boral, Chief Medical Officer of Blueprint Medicines, shared an update on the BLU-285 program, including a summary of updated clinical trial results recently presented at The Connective Tissue Oncology Society 2017 Annual Meeting on November 10.

Dr. Boral also provided an update on ongoing and planned BLU-285 clinical trials.   Patients with GIST and their families participated in the event, and some submitted questions in advance for the Q&A portion of the webcast.

A replay of the webcast will shortly be made available in the “Patients” section of the Blueprint Medicines website under “Patient Community Events” located at: http://www.blueprintmedicines.com/patients/patient-community-events.

Blueprint recently released impressive early trial data for BLU285

http://markets.businessinsider.com/news/stocks/Blueprint-Medicines-Announces-New-Data-from-Ongoing-Phase-1-Clinical-Trial-of-BLU-285-in-Patients-with-Advanced-Gastrointestinal-Stromal-Tumors-Showing-Strengthened-Clinical-Activity-across-1007556510

“”The data showed 67 percent of patients with heavily pretreated KIT-driven GIST treated with 300 to 400 mg of BLU-285 once daily (QD) had radiographic tumor reductions. In this population, the data also showed an objective response rate (ORR) of 17 percent and median progression free survival (PFS) of 11.5 months. In patients with PDGFRα-D842 driven GIST, the data showed an ORR of 71 percent and an estimated 12-month PFS of 78 percent.””

“”Across all grades, the most common treatment-emergent AEs reported by investigators (≥20 percent) included nausea (56 percent), fatigue (53 percent), periorbital edema (43 percent), vomiting (41 percent), edema peripheral (34 percent), anemia (31 percent), diarrhea (31 percent), increased lacrimation (30 percent), cognitive effects (30 percent), decreased appetite (28 percent), dizziness (23 percent), constipation (22 percent) and hair color changes (22 percent).  Cognitive effects are an aggregated category of individual cognitive events, each of which was observed in fewer than 20 percent of patients.””